首页> 外文OA文献 >Efficacy and safety of a herbal mixture (Vironreg; tablets) in the treatment of patients with chronic hepatitis C virus infection: a prospective, randomized, open-label, proof-of-concept study

【2h】

Efficacy and safety of a herbal mixture (Vironreg; tablets) in the treatment of patients with chronic hepatitis C virus infection: a prospective, randomized, open-label, proof-of-concept study

机译：草药混合物（viron®片剂）治疗慢性丙型肝炎病毒感染患者的疗效和安全性：预期，随机，开放标签，概念证明研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Mostafa Yakoot; Hisham Shawkat; Tarek Shawkat; Sherine Helmy;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of a herbal mixture (Viron? tablets) in the treatment of patients with chronic hepatitis C virus infection: a prospective, randomized, open-label, proof-of-concept study [J] . Hisham Shawkat, Mostafa Yakoot, Tarek Shawkat, Drug Design, Development and Therapy . 2015,第9期

机译：草药混合物（Viron？片剂）对慢性丙型肝炎病毒感染患者的疗效和安全性：一项前瞻性，随机，开放标签，概念验证性研究
2. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial (vol 385, 1087, 2015) [J] . Sulkowski M., Hezode C., Gerstoft J. The Lancet . 2015,第9973期

机译：在患有或不患有病毒唑的丙型肝炎病毒基因型1型单一感染和HIV /丙型肝炎病毒合并感染的患者中，分别使用grazoprevir（MK-5172）和elbasvir（MK-8742）联合或不联合病毒唑治疗8周和12周的疗效和安全性C-WORTHY）：一项随机，开放标签的2期临床试验（第385卷，1087，2015年）
3. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial [J] . Sulkowski Mark, Hezode Christophe, Gerstoft Jan, The Lancet . 2015,第9973期

机译：在患有或不患有病毒唑的丙型肝炎病毒基因型1型单一感染和HIV /丙型肝炎病毒合并感染的患者中，分别使用grazoprevir（MK-5172）和elbasvir（MK-8742）联合或不联合病毒唑治疗8周和12周的疗效和安全性（ C-WORTHY）：一项随机，开放标签的2期临床试验
4. Herbal Medicine Containing Aristolochic Acid and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Infection: A Nationwide Population-Based Cohort Study in Taiwan [C] . Wen-Chao Ho, Chi-Jen Chen, Yao-Hsu Yang, Joint annual meeting of the International Society of Exposure Science and the International Society for Environmental Epidemiology . 2018

机译：含有马兜铃酸的草药和丙型肝炎病毒感染患者肝细胞癌的风险：台湾全国性人群研究
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Efficacy and safety of a herbal mixture (Viron® tablets) in the treatment of patients with chronic hepatitis C virus infection: a prospective randomized open-label proof-of-concept study [O] . Hisham Shawkat, Mostafa Yakoot, Tarek Shawkat, 2015

机译：草药混合物（Viron®片剂）对慢性丙型肝炎病毒感染患者的疗效和安全性：一项前瞻性随机开放标签概念验证性研究
7. Safety and efficacy of direct-acting antiviral drugs in the treatment of chronic hepatitis C virus infection in patients with thalassemia: a prospective study [O] . Elsayed Ghoneem, Ahmed Saleh, Shahira Aly El-Etreby, 2021

机译：直接作用抗病毒药物治疗慢性丙型肝炎患者慢性丙型肝炎病毒感染的安全性和有效性：预期研究

Efficacy and safety of a herbal mixture (Vironreg; tablets) in the treatment of patients with chronic hepatitis C virus infection: a prospective, randomized, open-label, proof-of-concept study

著录项

引文网络

相似文献

相关主题

期刊订阅